SuperworthTenax Therapeutics revenue TENX
Sales by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jan 31, 2015
- n/m
- a quarter missing
- Latest quarter, Q3 FY15
- $0
- −100% on a year earlier
- Fiscal year 2013
- $1.2M
- +227% on the year before
Tenax Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q3 FY15, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2013 | $1.2M | +227% |
| FY2012 | $363.8K | +253% |
| FY2011 | $103.2K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY15 | $0 | −100% | n/a | |
| Q2 FY15 | $0 | −100% | n/a | |
| Q1 FY15 | $0 | −100% | n/a | |
| Q3 FY14 | $41.9K | −81% | $444.9K | |
| Q2 FY14 | $55.7K | −89% | $625.5K | |
| Q1 FY14 | $165.8K | −39% | $1.1M | |
| Q4 FY13 | $181.6K | +90% | $1.2M | |
| Q3 FY13 | $222.4K | +50% | $1.1M | |
| Q2 FY13 | $514.9K | +441% | $1M | |
| Q1 FY13 | $272.1K | +994% | $611K | |
| Q4 FY12 | $95.5K | +115% | $363.8K | |
| Q3 FY12 | $148.3K | +458% | $312.6K |
Against its peers
Companies in Drug Manufacturers - General nearest Tenax Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| TENXTenax Therapeutics | n/m | |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| Peer median | $274M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Tenax Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.